Sema4 announces non-reliance on previously issued financial statements and reports Q4 2021 results

GeneDx Holdings Corp.

Non-reliance on previously issued financial statements for years ended Dec 31, 2020 and 2019 due to expense classification errors in cost of services and selling & marketing.
Identified adjustments in cost of services recognition for Q1-Q3 2021; restated financials to be included in 2021 10-K filed March 14, 2022.
Q4 2021 test volumes (ex-COVID) up 37% YoY; total revenue $57.8M, net loss $40.2M vs $125.7M loss in prior year.
Full year 2021 revenue $212.2M up from $179.3M; net loss $245.4M vs $241.3M.
Reiterates FY2022 revenue guidance $215-225M; expects to close GeneDx acquisition by end of Q2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.